<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6462">
  <stage>Registered</stage>
  <submitdate>19/01/2014</submitdate>
  <approvaldate>19/01/2014</approvaldate>
  <nctid>NCT02043665</nctid>
  <trial_identification>
    <studytitle>Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200)</studytitle>
    <scientifictitle>A Phase 1, Dose-finding and Signal-seeking Study of the Safety and Efficacy of Intravenous CAVATAKÂ® (Coxsackievirus A21, CVA21) Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (NSCLC, Castrate-resistant Prostate Cancer, Melanoma, Bladder Cancer).</scientifictitle>
    <utrn />
    <trialacronym>STORM</trialacronym>
    <secondaryid>2012-005256-42</secondaryid>
    <secondaryid>VLA 009/ KEYNOTE-200</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-small Cell Lung Cancer</healthcondition>
    <healthcondition>Bladder Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - CVA21

Experimental: VLA 009A (Part A now complete), VLA 009B (Part B enrolling) - 


Other interventions: CVA21


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response rate assessed according to immune-related RECIST 1.1 criteria</outcome>
      <timepoint>Up to 6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant
             prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma.

          -  VLA009A: Locally advanced and/or metastatic disease for which curative surgery and/or
             radiation therapy is not possible and judged not to be a candidate for the current
             standard of care treatment. VLA009B: locally advanced and/or metastatic disease and
             judged to be a candidate for pembrolizumab to be used in combination with CVA21.

          -  All subjects in Cohort 3 or Phase 2 dose (P2D) must have a lesion accessible for FNA
             or core or open biopsy on day 8 of the first treatment cycle.

          -  No CVA21 neutralising antibody (= 1:16)

          -  Measurable or evaluable disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Second primary malignancy within the past 2 years (except non-melanoma skin cancer, in
             situ carcinoma of the cervix, breast cancer)

          -  Concurrent immunosuppressive therapy and no known immunosuppressive disease other than
             primary tumour</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC,WA</recruitmentstate>
    <hospital>Tasman Oncology Research - Southport</hospital>
    <hospital>Monash Health - Clayton</hospital>
    <hospital>St Vincent's Hospital, Melbourne - Fitzroy</hospital>
    <hospital>Barwon Health - Geelong</hospital>
    <hospital>Epworth HealthCare - Richmond</hospital>
    <hospital>St John of God Healthcare - Subiaco</hospital>
    <postcode>4216 - Southport</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3121 - Richmond</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chelsea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Viralytics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in
      combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while
      sparing normal cells) and to establish a safe multi-dose schedule of the virus for the
      treatment of solid tumors where enhanced expression of ICAM-1 and/ or DAF receptor occurs.

      This trial consists of 2 sequential parts: VLA-009 (Part A) conducted only in the UK and
      employed CVA21 as a monotherapy in NSCLC, castrate-resistant prostate cancer, melanoma and
      bladder cancer. VLA-009 (Part B) conducted in the US, AUS and UK employs CVA21 with
      pembrolizumab in NSCLC and bladder cancer.

      Both VLA-009A and VLA-009B are open-label, multi-center, ascending dose escalation (3+3
      design) dose-finding and signal-seeking studies.

      Part A of the study is now complete and closed to enrolment. Part B is currently enrolling.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02043665</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hardev Pandha, FRCP, FRACP, PhD, FSB</name>
      <address>Royal Surrey County Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Guttman</name>
      <address />
      <phone />
      <fax />
      <email>Lisa.Guttman@viralytics.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>